Company Overview and News
June 1 (Reuters) - Canada’s main stock index edged higher on Friday as gains in shares of energy companies more than offset losses in the heavyweight financials index.
SRHIF NGD NGDAF BCB DRGDF NGD NMKEF SU RNX RNX.WT COT RNKLF DGC NMX LB SU
SANTA MONICA, Calif. and TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") (CSE:TNY) (OTCQX:TNYBF) is pleased to announce that long-time Cott Board and Executive member Mark Benadiba, and California cannabis industry leader Ben Knight have joined the Company’s advisory board.
TNYBF COT QRSRF E ABCO BCB ETOLF TNY
Pilgrim's Pride Corporation (PPC - Free Report) is scheduled to report first-quarter 2018 results on Apr 10, after the market closes. The company reported better-than-expected results in three of the last four quarters, while lagging in one. Average earnings surprise was a positive 8.62%. Notably, in the last reported quarter, the company’s earnings of 58 cents per share surpassed the Zacks Consensus Estimate by 9.
TSNU COT SAFM MYGN BCB PPC TSN
TORONTO, May 07, 2018 (GLOBE NEWSWIRE) -- The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) is pleased to announce the addition of several key executives including CFO, General Counsel, VP of Sales, VP of Marketing, VP of Operations, and Regional Sales Manager for Ontario and Western Canada.
ACB MLFNF COT TEVJF MFI ACBFF TEVA TEVVF BCB ADWPF
Welcome to Cott Corporation's First Quarter 2018 Earnings Conference Call. All participants are currently in listen-only mode. This call will end no later than 11:00 am Eastern time. This call is being webcast live on Cott's website at www.cott.com and will be available for a playback there until May 17, 2018.
CRVP COT BCB
Dr Pepper Snapple Group Inc.’s (DPS - Free Report) first-quarter 2018 earnings missed the Zacks Consensus Estimate while revenues beat the same. Revenues benefited from a growth in sales volumes, favorable product and package mix, segment mix as well as foreign currency translation. Recently, the company announced its acquisition agreement with the well-known coffee maker Keurig Green Mountain, Inc.
COT MNST KO BCB GMCR
The Coca-Cola Company (KO - Free Report) kicked off 2018 on a strong note, beating the Zacks Consensus Estimate on both counts in the first quarter. Apart from a significant rise in soda volumes, the cola giant gained from its growing beverage portfolio and restructuring efforts. Cost-cutting initiatives led by refranchising of its low-margin bottling operations, helped it to come up with better numbers.
COT PEP MNST BCB
The futures were up big Monday morning as fears of an all-out trade war start to subside. There are reports that the Trump administration has sent a letter to Chinese economic overseer Liu He setting out specific requests to help cut China’s massive trade surplus with the United States. They are asking for a tariff cut on U.S. automobiles, more Chinese purchases of U.S. semiconductors and more access to China’s financial sector by American companies.
DB MS.PRE MS.PRF BCB AMD MS.PRG JACK ZBRA MS.PRA SBRA DLTR COT MS.PRI MS.PRK DHI CCE AVGO TRI BOX MS BRCM SBRAP
WATERTOWN, Conn., March 21, 2018 (GLOBE NEWSWIRE) -- Crystal Rock Holdings, Inc. (NYSE MKT:CRVP) (“Crystal Rock”) today announced the completion of the cash tender offer by CR Merger Sub, Inc. (“Purchaser”), a wholly-owned subsidiary of Cott Corporation (NYSE:COT) (TSX:BCB) (“Cott”), for all of the outstanding shares of Crystal Rock for $0.97 per share in cash.
CRVP COT BCB
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to TSX:BCB / Cott Corp on message board site Silicon Investor.
|Cott Corp. COTTF||BCB VOICE SYSTEMS INC. (c.BIV)|